Famitinib clinical trials
Famitinib is named as an intervention in 11 current clinical trials in our China register. 8 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Fudan University (8). The most-studied condition is Breast Cancer.
How Famitinib works
All drug targets →- Stem cell growth factor receptor inhibitor InhibitorTarget: KIT KIT proto-oncogene, receptor tyrosine kinase✓ In ChEMBL and the Guide to Pharmacology
- Vascular endothelial growth factor receptor 1 inhibitor InhibitorTarget: FLT1 fms related receptor tyrosine kinase 1ChEMBL only
- Tyrosine-protein kinase receptor FLT3 inhibitor InhibitorTarget: FLT3 fms related receptor tyrosine kinase 3ChEMBL only
- Platelet-derived growth factor receptor inhibitor InhibitorTarget: Platelet-derived growth factor receptor✓ In ChEMBL and the Guide to Pharmacology
- Vascular endothelial growth factor receptor 2 inhibitor InhibitorTarget: KDR kinase insert domain receptor✓ In ChEMBL and the Guide to Pharmacology
- Vascular endothelial growth factor receptor 3 inhibitor InhibitorTarget: FLT4 fms related receptor tyrosine kinase 4ChEMBL only
- Breast cancerPhase 3
- Cervical cancerPhase 3
- Colorectal adenocarcinomaPhase 3
- Gastrointestinal stromal tumorPhase 3
- Non-small cell lung carcinomaPhase 3
- Triple-negative breast carcinomaPhase 3
- CancerPhase 2
- Colorectal cancerPhase 2
- Differentiated thyroid carcinomaPhase 2
- Digestive system neuroendocrine neoplasmPhase 2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL1278146, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 7886, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Famitinib
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Famitinib
- ChEMBL
- CHEMBL1278146
- DrugBank
- DB11741
- PubChem CID
- 16662431
- CAS number
- 1044040-56-3
- FDA UNII
- 768FW21J3L
- Wikidata
- Q27077275
- Wikipedia
- Famitinib
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Famitinib
11 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Famitinib
16 conditionsAll 16 conditions
| Condition (as registered) | Trials |
|---|---|
| Breast Cancer | 3 |
| HER2-negative Breast Cancer | 3 |
| Breast Neoplasm | 2 |
| Neoadjuvant Therapy | 2 |
| Esophageal Squamous Cell Carcinoma | 1 |
| Breast Tumors | 1 |
| Triple-Negative Breast Cancer (TNBC) | 1 |
| BRCA-Mutated Breast Carcinoma | 1 |
| Triple-Negative Breast Cancer | 1 |
| Advanced Intrahepatic Cholangiocarcinoma | 1 |
| Intrahepatic Cholangiocarcinoma (Icc) | 1 |
| Advanced Breast Cancer | 1 |
| Metastatic Breast Cancer | 1 |
| Triple Negative Breast Cancer (TNBC) | 1 |
| Hormone Receptor Positive Tumor | 1 |
| Pancreatic Cancer | 1 |
Sponsors
lead sponsor per trialBy country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 11 | 8 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Famitinib trials
How many clinical trials are testing Famitinib?
11 current trials in our China register name Famitinib as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Famitinib trials recruiting patients?
Yes. 8 of the 11 trials are recruiting: 8 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Famitinib clinical trials?
Fudan University (8), First Affiliated Hospital Xi'an Jiaotong University (1), The First Affiliated Hospital with Nanjing Medical University (1) and The First Affiliated Hospital of Zhengzhou University (1). The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Famitinib works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Famitinib works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Famitinib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.